{"title":"Dostarlimab for the Treatment of Endometrial Cancer: A Review.","authors":"Chelsea E Stewart, Dana Chase","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>There have been many recent changes in the treatment of endometrial cancer, most recently with the US Food and Drug Administration's (FDA) approval of dostarlimab in conjunction with standard-of-care chemotherapy in the frontline setting for mismatch repair-deficient (dMMR) populations. This review sought to summarize the publications and studies that have led to this practice-changing approval. Dostarlimab is an immune checkpoint inhibitor with a favourable safety profile and proven efficacy in the treatment of endometrial cancer, particularly dMMR endometrial cancer. FDA-approved treatments for mismatch repair-proficient endometrial cancer remain limited.</p>","PeriodicalId":519941,"journal":{"name":"Touch reviews in oncology & haematology","volume":"20 1","pages":"9-11"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11160968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141297759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}